In cerebral palsy, the term cerebral refers to brain and palsy refers to the loss or impairment of motor function. Cerebral palsy is a group of neurological disorders that appear in infancy or early childhood, and permanently affect body movement and muscle coordination.
It is caused by damage or abnormalities inside the developing brain that disrupt its ability to control movement and maintain posture and balance. Cerebral palsy affects the motor area of the brain’s outer layer (called the cerebral cortex), that directs muscle movement.
Get the detailed analysis @ https://www.pharmaproff.com/report/cerebral-palsy-therapeutics-pipeline-analysis
In some cases, the cerebral motor cortex is not developed normally during fetal growth. In other case the damage is a result of injury to the brain either before, during, or after birth. In either case, the damage is not repairable and the disabilities that result are permanent.
Children with cerebral palsy exhibit a wide variety of symptoms like lack of muscle coordination when performing voluntary movements (ataxia), stiff or tight muscles and exaggerated reflexes (spasticity), weakness in one or more arm or leg, walking on the toes, and a crouched gait. Some drug candidates of cerebral palsy pipeline include, but are not limited to, Incobotulinumtoxin A and botulinum toxin type A.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Achondroplasia therapeutics currently exhibits a considerably strong pipeline with seven active drug candidates.
Achondroplasia is a common disorder of dwarfism with disproportionate stature. It is an autosomal dominant disorder that occurs due to mutation in fibroblast growth factor receptor 3 (FGFR3) gene, which is located on short arm of chromosome 4. The disorder is characterized by macrocephaly, shortened-limbs (rhizomelic dwarfism), midface retrusion, and frontal bossing. The achondroplasia therapeutics pipeline study covers seven active drug candidates in different stages of development.
Download the sample report @ https://www.pharmaproff.com/request-sample/1153
Achondroplasia therapeutics pipeline has majority of candidates in the Pre-Clinical stage of development. A peptide-based drug candidate namely, vosoritide, is in the Phase III stage of development by BioMarin Pharmaceutical Inc., for the treatment of achondroplasia.
Get the detailed analysis @ https://www.pharmaproff.com/report/achondroplasia-therapeutics-pipeline-analysis
According to the research findings, majority of the drug candidates for the treatment of achondroplasia are being developed to be administered by the subcutaneous route. Some of the key advantages of subcutaneous route are sustained release of drug, improved patient condition, lower risk of systemic infections, less painful administration, and less-expensive nature of the administered drugs.
It has been observed that many pharmaceutical companies are adopting advanced technologies for the development of achondroplasia therapeutics. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. For instance, RIBOMIC Inc.’s, RiboART system, is the essential element in drug discovery technology, that helps in the discovery of various new drugs for the treatment of the various diseases including achondroplasia.
Some of the key players involved in the development of achondroplasia therapeutics include BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, and Therachon AG.
Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.
Download the free sample report @ https://www.pharmaproff.com/request-sample/1174
Several studies have demonstrated overexpression and amplification of aurora kinase in various haematological and solid cancers. Aurora kinase inhibitors when combined with other anti-cancer agents gives more positive results in variety of cancers. Better evaluation of aurora kinase inhibitors is required which raises the need of biomarkers, effective and novel therapeutic agents. Also, aurora kinase inhibitors selectivity targets cancer cells rather than healthy tissues, providing potential opportunities for more effective drug development with reduced adverse effects.
Get the detailed analysis @ https://www.pharmaproff.com/report/aurora-kinase-inhibitor-therapeutics
AstraZeneca PLC is in the process of developing AZD-2811 as a small molecule which acts as an aurora B inhibitor for the treatment of solid tumors. Some of the other companies having pipeline of aurora kinase inhibitors include AbbVie Inc., Merck & Co., Inc., and CASI Pharmaceuticals Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in treatment of digestive disorders, allergic disorders, oral disorders, colic, common cold, and liver diseases. Lactobacillus plantarum W1 is a probiotic that reduces the excess cholesterol levels, stimulate TH1 cells, and restore the intestinal permeability of human gut.
Get the research report at: https://www.pharmaproff.com/request-sample/1189
Schistosomiasis is an acute and chronic disease caused by parasitic worms of the genus Schistosoma, during routine domestic, occupational, agricultural, and recreational activities, which involves infested water exposure. School children are more prone to schistosomiasis due to lack of hygiene and certain play habits, such as swimming or fishing in infested water.
Download the research report at: https://www.pharmaproff.com/request-sample/1070
Dermatomycoses is a group of disease which is caused by dermatophytes, a fungus, which generally invade into keratinized tissues such as nails, skin and hairs. The causative agents for dermatomycoses include organisms of three genera, Microsporum, Trichophyton, and Deuteromycetes.
Dermatomycoses is a contagious disease that can be acquired from infected animals. Scaly skin, and itching are the most common symptoms of dermatomycoses. Matinas BioPharma Inc. is in the process of developing amphotericin B antifungal agent for the treatment of chronic mucocutaneous candidiasis.
Get the detailed analysis at: https://www.pharmaproff.com/report/dermatomycoses-therapeutics-pipeline-analysis
Moreover, F2G Ltd. is currently developing F901318 antifungal agent for the treatment of invasive aspergillosis. Pulmocide Ltd., Novan Inc., and Taro Pharmaceuticals USA, Inc., are some other players have drugs in their pipeline for the treatment of dermatomycoses.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.